1
|
Sampiron EG, Calsavara LL, Baldin VP, Montaholi DC, Leme ALD, Namba DY, Alves Olher VG, Caleffi-Ferraciolli KR, Cardoso RF, Siqueira VLD, Vandresen F, Scodro RBDL. Isoniazid-N-acylhydrazones as promising compounds for the anti-tuberculosis treatment. Tuberculosis (Edinb) 2023; 141:102363. [PMID: 37311289 DOI: 10.1016/j.tube.2023.102363] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2023] [Revised: 05/29/2023] [Accepted: 06/05/2023] [Indexed: 06/15/2023]
Abstract
Tuberculosis (TB), a disease caused by Mycobacterium tuberculosis complex, still presents significant numbers of incidence and mortality, in addition to several cases of drug resistance. Resistance, especially to isoniazid, which is one of the main drugs used in the treatment, has increased. In this context, N-acylhydrazones derived from isoniazid have shown important anti-Mycobacterium tuberculosis activity. Hence, this work aimed to determine the anti-TB potential of 11 isoniazid-N-acylhydrazones (INH-acylhydrazones). For this purpose, the determination of minimum inhibitory concentration (MIC) against M. tuberculosis H37Rv and clinical isolates was carried out. Drug combination, minimum bactericidal concentration, cytotoxicity, and in silico parameters were also performed. INH-acylhydrazones (2), (8), and (9) had MIC for M. tuberculosis H37Rv similar to or lower than isoniazid, and bactericidal activity was observed. In addition, these compounds showed low cytotoxicity, with a selectivity index greater than 3,000. Interesting results were also obtained in the drug combination assay, with synergistic combinations with isoniazid, ethambutol, and rifampicin. In the in silico study, INH-acylhydrazones behaved similarly to INH, but with improvements in some aspects. Based on these findings, it is concluded that compounds (2), (8), and (9) are considered promising scaffolds and warrant further investigation for designing future antimicrobial drugs.
Collapse
Affiliation(s)
- Eloísa Gibin Sampiron
- Postgraduate Program in Health Sciences, State University of Maringá (UEM), Maringá, Paraná, 87020-900, Brazil.
| | | | | | - Débora Cássia Montaholi
- Postgraduate Program in Health Sciences, State University of Maringá (UEM), Maringá, Paraná, 87020-900, Brazil
| | | | - Danillo Yuji Namba
- Department of Chemistry, Federal Technological University of Paraná, Londrina, Paraná, 86057-970, Brazil
| | | | - Katiany Rizzieri Caleffi-Ferraciolli
- Postgraduate Program in Bioscience and Physiopathology, UEM, Maringá, Paraná, 87020-900, Brazil; Department of Clinical Analysis and Biomedicine, UEM, Maringá, Paraná, 87020-900, Brazil
| | - Rosilene Fressatti Cardoso
- Postgraduate Program in Health Sciences, State University of Maringá (UEM), Maringá, Paraná, 87020-900, Brazil; Postgraduate Program in Bioscience and Physiopathology, UEM, Maringá, Paraná, 87020-900, Brazil; Department of Clinical Analysis and Biomedicine, UEM, Maringá, Paraná, 87020-900, Brazil
| | - Vera Lucia Dias Siqueira
- Postgraduate Program in Bioscience and Physiopathology, UEM, Maringá, Paraná, 87020-900, Brazil; Department of Clinical Analysis and Biomedicine, UEM, Maringá, Paraná, 87020-900, Brazil
| | - Fábio Vandresen
- Department of Chemistry, Federal Technological University of Paraná, Londrina, Paraná, 86057-970, Brazil
| | - Regiane Bertin de Lima Scodro
- Postgraduate Program in Health Sciences, State University of Maringá (UEM), Maringá, Paraná, 87020-900, Brazil; Department of Clinical Analysis and Biomedicine, UEM, Maringá, Paraná, 87020-900, Brazil
| |
Collapse
|